Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Dipyridamole 200mg;
Boehringer Ingelheim (NZ) Ltd
Dipyridamole 200 mg
200 mg
Modified release capsule
Active: Dipyridamole 200mg Excipient: Acacia Acetone Dimeticone Ethanol Gelatin Hypromellose Hypromellose phthalate Iron oxide red Iron oxide yellow Isopropyl alcohol Methacrylic acid copolymer Povidone Purified talc Purified water Stearic acid Tartaric acid Titanium dioxide Triacetin
Tube, plastic, 1x60, 60 capsules
Prescription
Prescription
Boehringer Ingelheim France
Package - Contents - Shelf Life: Tube, plastic, 1x60 - 60 capsules - 36 months from date of manufacture stored at or below 25°C
1996-03-07
NEW ZEALAND DATASHEET NAME OF MEDICINE PERSANTIN ® Dipyridamole PRESENTATION _Tablet 25 mg_ : Round, orange, shiny, biconvex sugar-coated tablet. _Perlonget_ ® _ (modified release capsule) 150 mg_ : Pink/white, opaque, hard gelatine capsule filled with yellow pellets. _Perlonget_ ® _ (modified release capsule) 200 mg_ : Red/orange, hard gelatine capsule filled with yellow pellets. USES ACTIONS Dipyridamole, the active ingredient of PERSANTIN, inhibits the uptake of adenosine into the erythrocytes, platelets and endothelial cells in vitro and in vivo; the inhibition amounts to 80% at its maximum and occurs dose-dependently at therapeutic concentrations (0.5 - 2 mcg/ml). Consequently, there is an increased concentration of adenosine locally at the platelet A2-receptor, stimulating platelet adenylate cyclase, thereby increasing platelet cAMP levels. Thus, platelet aggregation in response to various stimuli such as PAF, collagen and ADP is inhibited. Reduced platelet aggregation reduces platelet consumption towards normal levels. In addition, adenosine has a vasodilator effect and this is one of the mechanisms by which dipyridamole produces vasodilation. Dipyridamole inhibits phosphodiesterase (PDE) in various tissues. Whilst the inhibition of cAMP- PDE is weak, therapeutic levels inhibit cGMP-PDE, thereby augmenting the increase in cGMP produced by EDRF (endothelium-derived relaxing factor, identified as NO). Dipyridamole also stimulates the biosynthesis and release of prostacyclin by the endothelium. Dipyridamole reduces the thrombogenicity of subendothelial structures by in Read the complete document